NCR3LG1 and neoplasm: Unlike systemic IL-15 therapies (e.g., ALT-803) that promote Treg expansion and hepatotoxicity (14, 43, 44), our design confines IL-15 activity to B7-H6+ tumors, analogous to PD-L1-targeted IL-12 strategies that improve tumor-specific immunity (18, 19).